Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|April 24, 2015

Dicerna Receives Orphan Drug Designation for PH1 Treatment

Dicerna Pharmaceuticals announces that FDA granted its primary hyperoxaluria type 1 (PH1) treatment Orphan Drug designation.

 

Dicerna Pharmaceuticals announced on April 23, 2015 that it received FDA Orphan Drug designation for its primary hyperoxaluria type 1 (PH1) treatment, DCR-PH1. FDA grants Orphan Drug designation to drugs that are intended for the treatment of diseases or disorders that affect fewer than 200,000 people in the United States, or that affect more than 200,000 persons but that will not recover the costs of developing and marketing the drug.

There are no approved therapies for PH1, which is a severe, rare, inherited disorder that often results in kidney failure. DCR-PH1 is a lipid nanoparticle technology that can be efficiently delivered to the liver via an intravenous administration. According to a press release, the treatment is in preclinical development and is engineered to “address the pathology of PH1 by targeting and destroying the messenger RNA (mRNA) produced by HAO1, a gene implicated in the pathogenesis of PH1. HAO1 encodes glycolate oxidase, a protein involved in producing oxalate. By reducing oxalate production, this approach seeks to prevent the complications of PH1.”

Source: Dicerna Pharmaceuticals


Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.